title: Targeting molecular aberrations in urothelial carcinoma: are we almost there?
abstract: Advances in tumor biology and cancer genetics have led to the development of effective targeted therapies in oncology over the past decade. However, targeted drug development for urothelial carcinoma has been slower than for some other malignancies. The path forward in drug development is through a better understanding of the aberrant pathways driving urothelial tumor development. Steady progress has been made in the characterization of genomic alterations in urothelial carcinoma. The Cancer Genome Atlas (TCGA) project is well underway in the analysis of a large set of urothelial cancer specimens using multiple approaches and technologies. In addition, there are already many well-established mutations and genetic alterations in urothelial carcinoma that likely contribute in an important way to tumor development. In addition, urothelial cancer genome-wide association studies have identified common variants associated with urothelial cancer risk and protein expression that can potentially be therapeutically targeted. Furthermore, the MET pathway has emerged as an exciting target in multiple tumors, including urothelial carcinoma. Our knowledge of how to clinically target many emerging molecular aberrations in urothelial cancer is still in the early stages of development. However, there is much promise in the ongoing research being conducted in urothelial cancer molecular pathogenesis.
authors.affiliation: From the Medical Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD; the Translational Medicine Division, Brigham and Women's Hospital, Harvard Medical School, Dana-Farber Cancer Institute, Boston, MA.
authors.forename: Andrea B
authors.initials: AB
authors.lastname: Apolo
authors.forename: David J
authors.initials: DJ
authors.lastname: Kwiatkowski
mesh_terms: D000970:Antineoplastic Agents / Q000494:pharmacology / Q000627:therapeutic use; D015972:Gene Expression Regulation, Neoplastic; D055106:Genome-Wide Association Study; D006801:Humans; D058990:Molecular Targeted Therapy / Q000379:methods*; D057285:Precision Medicine; D019859:Proto-Oncogene Proteins c-met / Q000235:genetics / Q000378:metabolism; D014571:Urologic Neoplasms / Q000235:genetics* / Q000473:pathology / Q000628:therapy*; D019459:Urothelium / Q000473:pathology*
chemical_list: D000970:Antineoplastic Agents; C491743:MET protein, human; D019859:Proto-Oncogene Proteins c-met